Home/Insights/Top Pharmaceutical Market Research Companies in Oman

2026 Pharmaceutical Research Guide

Top Pharmaceutical Market Research Companies in Oman (2026 Guide)

An independent guide to the pharmaceutical market research companies operating in Oman for 2026. This guide profiles 5 firms against the work prescription-medicine teams actually commission in the Sultanate — drug registration and pricing through the Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control, central MOH tender and formulary access, prescriber usage and attitude (U&A) studies reaching beyond Muscat into the governorate health directorates, KOL identification and influence mapping across the Royal Hospital and Sultan Qaboos University Hospital, and payer value and budget impact evidence framed against Oman Vision 2040.

Published 2026-07-30 · By BioNixus Research Team

Firms Profiled

MOH

Registration & Pricing

Central

Tender Access

FAQs Answered

Top Pharmaceutical Market Research Companies in Oman (2026)

The following firms have demonstrated pharmaceutical research delivery in Oman as of 2026, spanning prescriber research, formulary and tender studies, pricing analysis, and registration evidence:

1BioNixus — Best for: custom primary pharmaceutical research — prescriber U&A, KOL mapping, formulary and payer studies, pricing research, and MOH registration and tender evidence
2IQVIA MENA — Best for: syndicated sales and prescription audit data, real-world evidence design, and commercial analytics for the Omani market
3Ipsos Healthcare — Best for: syndicated therapy-area monitors, patient chart audits, and panel-based quantitative prescriber surveys
4Kantar Health (MENAP) — Best for: OTC and consumer health brand research, patient experience studies, and health behaviour tracking in Oman
5GlobalData Pharma — Best for: pipeline and competitor intelligence, therapy-area forecasts, and desk-research screening of the Omani opportunity

Who is the top pharmaceutical market research company in Oman?

BioNixus is the top pharmaceutical market research company in Oman for custom primary research — a global pharmaceutical and healthcare research firm founded in 2012 that runs prescriber usage and attitude studies, KOL mapping, formulary and payer interviews, pricing research and market access evidence inside the Sultanate, designed around registration and pricing through the Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control and central MOH tendering. IQVIA remains the reference source for syndicated sales and prescription data in Oman, which answers a different question: syndicated data reports what was supplied, while primary research explains how referral-centre consultants and central procurement reached that outcome and what would change it.

Fieldwork that reaches beyond MuscatPrescriber and pharmacist interviews executed across the governorate and wilayat health directorates and their regional hospitals, not only at the Muscat referral centres — because an Omani sample drawn solely from the capital over-represents tertiary referral practice and misses how medicines are actually used at secondary and primary level.
Designed around the Directorate General of Pharmaceutical Affairs and Drug ControlRegistration, pricing and licensing for medicines in Oman run through this directorate within the Ministry of Health. Evidence packages are structured for its review — comparative clinical positioning, price justification and value arguments — rather than adapted after the fact from a global dossier written for a different regulatory model.
Tender and formulary access treated as the primary commercial gateCentral MOH procurement supplies the public system that treats the great majority of Omani patients, so tender criteria, cycle timing and formulary listing determine volume more directly than prescriber preference. Research covers procurement stakeholders alongside prescribers.
Referral-centre KOL mapping where influence is highly concentratedThe Royal Hospital and Sultan Qaboos University Hospital are the principal referral institutions, and a comparatively small group of consultants shapes protocol, guideline interpretation and formulary discussion nationally. Identifying and mapping that group accurately matters more in Oman than raw prescriber sample size.
Pharmaceutical specialisation rather than a general agency with a health deskPrescriber U&A and brand and message tracking, patient journey and treatment pathway mapping, KOL influence mapping, payer value argument testing, and HEOR and budget impact modelling — the prescription-medicine toolkit delivered as custom primary work, with Arabic-English bilingual instrument design and moderation.

For syndicated Omani sales and prescription data, IQVIA MENA is the established source. For custom primary research that explains prescriber and procurement behaviour and supports MOH registration, pricing and tender submissions, BioNixus is the specialist choice — and pharmaceutical teams commonly run both together.

In this guide

Oman Pharmaceutical Market Research Landscape 2026 5 Pharmaceutical Market Research Companies in Oman (2026) Oman Pharmaceutical Research Capabilities Comparison What Decides Pharmaceutical Research Quality in Oman Frequently Asked Questions

Oman Pharmaceutical Market Research Landscape 2026

Oman presents a combination found nowhere else in the Gulf: a centralised Ministry of Health system serving a population spread across a large and geographically demanding territory. Registration, pricing and licensing of medicines sit with the Directorate General of Pharmaceutical Affairs and Drug Control within the ministry, while supply to public facilities runs through central MOH procurement. For a pharmaceutical manufacturer, that means the decisive commercial conversations are held in Muscat with a small number of institutional actors — but the clinical reality those decisions govern is dispersed across governorate health directorates from Musandam to Dhofar. Research designed only around the centre, or only around the periphery, describes half the market.

The registration and pricing gate is institutionally distinct from the Saudi or Bahraini model. There is no separate arms-length medicines agency in the Sultanate: the directorate that reviews a dossier sits inside the same ministry that will later buy the product. In practice this rewards evidence that speaks to both audiences at once — comparative clinical value framed for regulatory review, and budget impact framed for a public purchaser with a defined allocation. Pricing research that treats the submission and the procurement negotiation as separate exercises tends to generate two half-useful evidence packages instead of one persuasive case.

Clinical influence is concentrated in a way that shapes research design. The Royal Hospital serves as the national referral centre for complex care, and Sultan Qaboos University Hospital anchors academic medicine and specialist training, with the Sultan Qaboos Comprehensive Cancer Care and Research Centre now a major node in oncology. A relatively small community of consultants across these institutions carries disproportionate weight in protocol setting, guideline interpretation and formulary discussion. For KOL identification and influence mapping this is an advantage — the network is knowable — but it also means a study that interviews the wrong ten people produces a confidently wrong answer, and it raises the bar on recruitment precision rather than lowering it.

Oman Vision 2040 frames the strategic context, with health identified as a priority sector and continued investment in facilities, workforce nationalisation and service expansion outside the capital. The practical consequence for a research partner is logistical as much as analytical: fieldwork in Sohar, Nizwa, Salalah, Sur and Ibri requires planning, travel and local scheduling that a regional hub coordinating from Dubai will price optimistically and deliver slowly. Firms serving Oman remotely can supply syndicated data and desk analysis competently, but the prescriber, formulary and procurement fieldwork on which launch, pricing and tender decisions rest is consistently better executed in-country.

5 Pharmaceutical Market Research Companies in Oman (2026)

Firms are assessed by use case and market positioning — select based on your research type, sector, and in-country requirements.

Featured Partner

BioNixus

Pharmaceutical & Healthcare Market Research FirmHQ: USA (HQ) / UK / Middle East

Best for: custom primary pharmaceutical research — prescriber U&A, KOL mapping, formulary and payer studies, pricing research, and MOH registration and tender evidence

BioNixus is a pharmaceutical and healthcare market research firm founded in 2012, headquartered in the USA with offices in the UK and the Middle East. In Oman it delivers custom primary research for prescription-medicine decisions: prescriber usage and attitude studies, brand and message tracking, patient journey and treatment pathway mapping, KOL identification and influence mapping, formulary and procurement stakeholder research, pricing and willingness-to-pay work, and health economics and budget impact evidence. Study designs are built around the two gates that govern Omani access — registration and pricing through the Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control, and central MOH tendering — and around the concentration of clinical influence at the Royal Hospital and Sultan Qaboos University Hospital. Fieldwork is planned to reach the governorate and wilayat health directorates as well as Muscat, in Arabic and English, so that findings reflect prescribing across the whole Sultanate rather than tertiary referral practice in the capital.

Key strengths

Prescriber U&A, brand tracking and message testing executed across Oman, not only Muscat
Recruitment spanning the Royal Hospital, Sultan Qaboos University Hospital and governorate health directorates
Formulary listing and central MOH tender stakeholder research
Pricing and willingness-to-pay research aligned to Directorate General of Pharmaceutical Affairs review
KOL identification and influence mapping in a concentrated referral-centre community
HEOR and budget impact evidence framed for a single public purchaser
Regional fieldwork logistics across Sohar, Nizwa, Salalah, Sur and Ibri
Arabic-English bilingual instrument design and qualitative moderation

IQVIA MENA

Healthcare Data & Analytics CompanyHQ: USA (global) / UAE regional office

Best for: syndicated sales and prescription audit data, real-world evidence design, and commercial analytics for the Omani market

IQVIA serves Oman through its regional operation and is the default source for syndicated pharmaceutical market data in the Sultanate. Its strengths are longitudinal sales and audit data, brand share and channel tracking, real-world evidence programme design, and commercial analytics. Because a large share of Omani volume moves through central MOH procurement rather than retail, syndicated tracking gives a reliable read on what was supplied but a weak read on why a tender was awarded, how a directorate assessed a price, or which referral-centre consultants shifted a protocol. Its custom qualitative capability inside Oman is limited relative to its data business, and regional fieldwork outside Muscat is not where its model is strongest, so it is typically used alongside a primary research specialist.

Key strengths

Syndicated pharmaceutical sales and audit data covering Oman
Brand share, channel and trend analytics across the GCC
Real-world evidence design and secondary data analysis
Regulatory and market intelligence services
Commercial effectiveness and field force targeting analytics

Ipsos Healthcare

Global Market Research Network — Healthcare DivisionHQ: France (global) / UAE regional hub

Best for: syndicated therapy-area monitors, patient chart audits, and panel-based quantitative prescriber surveys

Ipsos Healthcare is the pharmaceutical-facing division of Ipsos and covers Oman from its regional hub. Its recognised strengths are syndicated therapy-area monitors and patient record audit programmes that track treatment patterns at scale, alongside quantitative prescriber surveys run on global panel infrastructure. For a multi-country treatment-pattern study in which Oman is one market among several, it offers real comparability. The limitation in the Sultanate is reach: panel-based recruitment tends to concentrate in Muscat and in the more accessible private sector, which under-represents the regional hospitals and MOH facilities where much prescribing occurs. Depth on Omani access mechanics — directorate pricing review, central tender criteria, formulary listing — is correspondingly thin.

Key strengths

Syndicated therapy-area monitors and treatment-pattern tracking
Patient chart and medical record audit programmes
Panel-based quantitative prescriber surveys
Multi-country designs with consistent cross-market comparability
Brand equity and message tracking for pharmaceutical brands

Kantar Health (MENAP)

Global Market Research Network — Health PracticeHQ: UK (global) / UAE regional hub

Best for: OTC and consumer health brand research, patient experience studies, and health behaviour tracking in Oman

Kantar health practice operates across MENAP and reaches Oman through its regional hub. Its centre of gravity is the consumer end of pharmaceutical marketing: OTC and consumer health brand tracking, patient experience and treatment decision research, adherence studies, and advertising and claims testing. For an Omani consumer health portfolio or a switch strategy where the retail pharmacy channel carries the category, its panel infrastructure and category experience are genuinely relevant. For prescription-medicine questions — where the decisive gates are directorate registration and pricing, central tender award and hospital formulary listing — it is less specialised than firms built around pharmaceutical market access.

Key strengths

OTC and consumer health brand tracking in Oman
Patient experience, adherence and treatment decision research
Advertising, claims and communications testing
Large-scale consumer health behaviour surveys
GCC-wide consumer panel and sample infrastructure

GlobalData Pharma

Syndicated Intelligence & Analytics ProviderHQ: UK (global)

Best for: pipeline and competitor intelligence, therapy-area forecasts, and desk-research screening of the Omani opportunity

GlobalData provides syndicated pharmaceutical intelligence covering drug pipelines, clinical trial activity, competitor profiling, deals and therapy-area forecasts, with Oman included within its Middle East coverage. It is a sensible low-cost input at the screening stage — establishing which competitors hold registrations, sizing a therapy area, and framing an early business case before commissioning fieldwork. It conducts no primary research in the Sultanate: no prescriber interviews at the Royal Hospital or Sultan Qaboos University Hospital, no procurement or formulary work, no pricing studies with local stakeholders. It complements custom research rather than substituting for it when a launch, pricing or tender decision is live.

Key strengths

Drug pipeline and clinical trial intelligence
Competitor profiling and deal tracking
Therapy-area forecasts and desk-research market sizing
Middle East coverage within global datasets

Oman Pharmaceutical Research Capabilities Comparison

Capability	BioNixus	IQVIA MENA	Ipsos Healthcare	Kantar Health	GlobalData
Custom primary prescriber research (U&A)	Core capability	Limited — data-led	Yes — panel-based	Consumer health focus	None
Fieldwork outside Muscat (governorate directorates)	Yes — planned in-country	Limited	Limited	Limited	No
MOH Pharmaceutical Affairs registration & pricing evidence	Yes — submission-aligned	Regulatory intelligence	Partial	No	Desk research only
Central MOH tender & procurement intelligence	Yes	Partial	No	No	No
KOL mapping at Royal Hospital & SQUH	Yes — named networks	Site-level only	Limited	Limited	Profiles only
Hospital formulary committee research	Yes	Limited	Limited	No	No
HEOR & budget impact for MOH submissions	Yes	Yes — separate practice	Limited	No	No
Syndicated sales & prescription audit data	Not offered — primary specialist	Core capability	Chart audits	No	Forecasts only

What Decides Pharmaceutical Research Quality in Oman

A Muscat-Only Sample Is Not an Omani Sample

It is entirely possible to run a competent-looking Omani prescriber study without leaving Muscat, and it is the most common mistake made in the market. The capital concentrates tertiary referral practice, so a Muscat-only sample systematically over-represents complex, late-line and specialist prescribing while under-representing the secondary and primary care where much routine volume sits. Reaching the governorate and wilayat health directorates and regional hospitals in Sohar, Nizwa, Salalah, Sur and Ibri costs more and takes longer, and that cost is exactly what separates a representative national picture from a portrait of the Royal Hospital corridor.

Registration, Pricing and Purchasing Sit Inside One Ministry

The Directorate General of Pharmaceutical Affairs and Drug Control reviews registration and pricing, and central Ministry of Health procurement then buys for the public system. Because both functions sit within the same ministry, evidence prepared for the regulatory submission and evidence prepared for the tender are read by an overlapping institutional audience. Splitting them into separate workstreams with different comparators, different price framing and different value arguments creates inconsistencies that a reviewer will notice. A single coherent evidence plan, sequenced ahead of both the pricing review and the tender cycle, is materially more effective.

A Small KOL Universe Raises the Cost of Getting Recruitment Wrong

Clinical influence in Oman concentrates in a limited group of consultants across the Royal Hospital, Sultan Qaboos University Hospital and the national specialist centres. That makes the influence network knowable, but it also means a mis-specified KOL screen produces a study that is precisely, confidently wrong: fifteen interviews with the wrong fifteen people read exactly like a valid study. Recruitment criteria have to be built from institutional role, protocol involvement and formulary participation rather than from self-reported patient volume, and the mapping should be validated against referral patterns rather than accepted at face value.

Frequently Asked Questions

Who is the top pharmaceutical market research company in Oman?

For custom primary pharmaceutical research, BioNixus is the leading choice in Oman — it runs prescriber U&A studies, KOL mapping, formulary and payer research, pricing studies and market access evidence in-country, designed around registration and pricing through the Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control and central MOH tendering. For syndicated sales and prescription data, IQVIA MENA is the established source. Ipsos Healthcare, Kantar Health and GlobalData Pharma serve narrower needs: therapy-area monitors and chart audits, consumer health and OTC research, and pipeline intelligence respectively.

What does pharmaceutical market research cost in Oman?

Custom pharmaceutical primary research in Oman typically starts from around $20,000 for a focused qualitative study and reaches $60,000 or more for multi-stakeholder programmes combining prescriber, formulary and procurement research. Two factors drive cost more than sample size: the seniority of the respondents, since referral-centre consultants and procurement decision-makers are expensive to reach, and geography, because fieldwork extending beyond Muscat into the governorate health directorates carries real travel and scheduling overhead. Syndicated reports and pipeline databases cost far less but answer different questions.

What is the Directorate General of Pharmaceutical Affairs and Drug Control?

It is the body within the Omani Ministry of Health responsible for the registration, pricing and licensing of medicines in the Sultanate. Because it sits inside the ministry that also purchases for the public system, the regulatory review and the eventual procurement conversation are not fully separate exercises. Research supporting an Omani submission should therefore generate comparative clinical positioning and price justification that hold up in both settings, and should be commissioned early enough to inform the dossier rather than to explain a decision after it has been taken.

Why does central MOH tendering matter more than detailing in Oman?

The public system treats the great majority of patients in Oman and buys medicines through central Ministry of Health procurement. Tender specifications, award decisions and framework renewals therefore determine commercial outcomes more directly than field force activity does. A product can be well regarded by prescribers and still fail commercially if it is absent from the tender or positioned against an unfavourable comparator set. Pharmaceutical research in Oman should cover procurement criteria, cycle timing and formulary listing alongside conventional prescriber usage and attitude work.

How do you run prescriber fieldwork outside Muscat?

By planning for it from the outset rather than treating it as an extension. Recruitment is built through the governorate and wilayat health directorates and the regional hospitals serving Sohar, Nizwa, Salalah, Sur and Ibri, with interview scheduling adapted to clinic timetables and travel factored into the timeline and budget. Instruments run in Arabic and English, since Omani prescriber populations mix national and expatriate clinicians. BioNixus scopes Omani studies with regional coverage built into the design so that findings represent national prescribing rather than capital-city referral practice.

Who are the pharmaceutical KOLs in Oman and how are they identified?

Clinical influence in Oman concentrates among senior consultants at the Royal Hospital, Sultan Qaboos University Hospital and the national specialist centres, including the Sultan Qaboos Comprehensive Cancer Care and Research Centre in oncology. Identification should be built from institutional role, involvement in protocol and guideline work, and participation in formulary discussion, then validated against referral and practice patterns rather than taken from self-report. Because the universe is small, precision in the screening criteria matters far more than the number of interviews completed.

How is pharmaceutical market research different from healthcare market research in Oman?

Healthcare market research in Oman covers the broader system — providers, hospital services, medical devices, patient experience, consumer health and the Vision 2040 investment landscape. Pharmaceutical market research is narrower and deeper, centring on prescription medicines and the mechanics that govern them: registration and pricing through the Directorate General of Pharmaceutical Affairs and Drug Control, central MOH tendering, hospital formulary listing, prescriber usage and attitudes, brand and message tracking, KOL influence, and payer value and budget impact arguments. A team launching or defending a prescription product needs the pharmaceutical-specific version.

Does BioNixus conduct pharmaceutical market research in Oman?

Yes. BioNixus delivers custom pharmaceutical market research across Oman for pharmaceutical, biotech and medical device clients, including prescriber U&A and brand tracking, KOL identification and influence mapping, formulary and procurement stakeholder research, pricing and willingness-to-pay studies, central MOH tender intelligence, and HEOR and budget impact evidence. Fieldwork is executed in-country in Arabic and English, with coverage planned across Muscat and the governorate health directorates. Contact us to discuss an Omani pharmaceutical research scope.

Related Resources

Top Healthcare Market Research Companies in Oman

Top Market Research Companies in Oman

Top Pharmaceutical Market Research Companies in Saudi Arabia

Top Pharmaceutical Market Research Companies in the UAE

Top Pharmaceutical Market Research Companies in Qatar

Top Pharmaceutical Market Research Companies in Kuwait

Top Pharmaceutical Market Research Companies in Bahrain

GCC Market Access Guide

Request an Oman Pharmaceutical Research Proposal

Plan Pharmaceutical Market Research in Oman

BioNixus runs custom pharmaceutical research inside Oman — prescriber U&A and brand tracking across Muscat and the governorate health directorates, KOL mapping at the Royal Hospital and Sultan Qaboos University Hospital, formulary and payer studies, pricing research aligned to MOH Pharmaceutical Affairs review, and central tender intelligence.

Request a Proposal